Evidence map›Paper›PMID 41264828›Full record

Trial reportDiabetes care2025

Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes.

Timothy E Graham, Dan Raghinaru, Samina Afreen, Andrew Ahmann, Ahmad Haidar, Philip Raskin, Michael A Tsoukas, John W Lum, Ravid Sasson-Katchalski, Jordan E Pinsker and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05785832 (A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05785832 nacompletednot on this map

A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)

TypeinterventionalSponsorTandem Diabetes Care, Inc.Ran2023 to 2024Enrolled319ConditionsType 2 Diabetes Treated With InsulinArmst:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Timothy E GrahamUtah Diabetes & Endocrine Treatment Specialists, Sandy, UT.
Dan RaghinaruJaeb Center for Health Research, Tampa, FL.
Samina AfreenDivision of Endocrinology, Center for Diabetes Technology, University of Virginia, Charlottesville, VA.
Andrew AhmannHarold Schnitzer Diabetes Health Center, Oregon Health & Science University, Portland, OR.
Ahmad HaidarDepartment of Biomedical Engineering and Division of Endocrinology, McGill University, Montreal, Quebec, Canada.
Philip RaskinUT Southwestern Medical Center, University of Texas, Southwestern, Dallas, TX.
Michael A TsoukasDepartment of Biomedical Engineering and Division of Endocrinology, McGill University, Montreal, Quebec, Canada.
John W LumJaeb Center for Health Research, Tampa, FL.
Ravid Sasson-KatchalskiTandem Diabetes Care, San Diego, CA.
Jordan E PinskerTandem Diabetes Care, San Diego, CA.ORCID 0000-0003-4080-9034
Roy W BeckJaeb Center for Health Research, Tampa, FL.ORCID 0000-0002-5194-8446
2IQP Study Group*

Funding

Tandem Diabetes Care
6 · The paper itself

Abstract

objectiveTo assess the effect of automated insulin delivery (AID) on glycemic and insulin outcomes in adults with insulin-treated type 2 diabetes using a glucagon-like peptide-1 receptor agonist (GLP-1 RA). RESEARCH DESIGN AND

methodsIn a randomized trial comparing Control-IQ+ AID versus continuation of prestudy insulin delivery method plus continuous glucose monitoring (CGM group), 143 (45%) of the 319 participants were using a GLP-1 RA at baseline, which was continued during the trial.

resultsAmong GLP-1 RA users, mean HbA1c decreased by 0.8% from a baseline of 8.0 ± 1.2% with AID, which represented a mean improvement of -0.5% (95% CI -0.8 to -0.3, P < 0.001) compared with the CGM group. Time-in-range 70-180 mg/dL and other CGM metrics reflective of hyperglycemia also showed comparable statistically significant improvements using AID when added to GLP-1 RA use. For GLP-1 RA users, there was no significant difference in weight after 13 weeks with AID compared with the CGM group (0.9 kg, 95% CI -0.2 to 2.1, P = 0.10), whereas, in GLP-1 RA nonusers, there was a mean weight gain of 1.9 kg with AID compared with CGM (95% CI 0.5 to 3.2, P = 0.007).

conclusionsThe benefits of AID appear to be substantial for a broad spectrum of insulin-treated patients with type 2 diabetes, including those already receiving contemporary and guideline-directed therapy, such as a GLP-1 RA medication. These additive benefits of AID in GLP-1 RA users included significant reductions in HbA1c levels with simultaneous reduction in insulin use, along with no statistical increase in weight despite very significant improvements in glycemic control.

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinInsulin Infusion SystemsAdultAgedBlood GlucoseFemaleGlycated HemoglobinHumansMaleMiddle AgedBlood GlucoseGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic AgentsInsulin

Identifiers

PMID41264828
PMCPMC12635876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.